ADPT

SEC source: 0001209191-21-008246 · doc4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,469

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-007548 · doc4.xml · derivative · entry 9

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 194,750

Underlying: Common Stock · 7,790 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-007548 · doc4.xml · nonDerivative · entry 7

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 679

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $60.34 to 60.82, inclusive.

SEC source: 0001209191-21-007548 · doc4.xml · nonDerivative · entry 6

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,058

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.31 to 60.22, inclusive.

SEC source: 0001209191-21-007548 · doc4.xml · nonDerivative · entry 5

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,559

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.21 to 59.20, inclusive.

SEC source: 0001209191-21-007548 · doc4.xml · nonDerivative · entry 4

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,469

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-007551 · doc4.xml · derivative · entry 9

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 15,000 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 7

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $59.91 to 60.06, inclusive.

SEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 6

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,010

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $58.90 to 59.88, inclusive.

SEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,290

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.88 to 58.87, inclusive.

SEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

SEC source: 0001209191-21-007548 · doc4.xml · derivative · entry 8

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 202,540

Underlying: Common Stock · 7,790 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-007548 · doc4.xml · nonDerivative · entry 3

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 679

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.98 to 56.42, inclusive.

SEC source: 0001209191-21-007548 · doc4.xml · nonDerivative · entry 2

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,269

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $54.98 to 55.97, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-007548 · doc4.xml · nonDerivative · entry 1

ROBINS HARLAN S · CIK 0001780851 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,469

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: These transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2020.

SEC source: 0001209191-21-007551 · doc4.xml · derivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 15,000 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F7 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.81 to 56.35, inclusive.

SEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,055

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $54.78 to 55.75 inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-007551 · doc4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

SEC source: 0001209191-21-007547 · doc4.xml · derivative · entry 8

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,938

Underlying: Common Stock · 1,562 shares

Expires 2029-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-007547 · doc4.xml · derivative · entry 7

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,084

Underlying: Common Stock · 2,604 shares

Expires 2028-10-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

F4 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-007547 · doc4.xml · derivative · entry 6

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,438

Underlying: Common Stock · 2,604 shares

Expires 2028-02-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

F3 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-007547 · doc4.xml · nonDerivative · entry 5

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-21-007547 · doc4.xml · nonDerivative · entry 4

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 300

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.26 to 56.16, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-007547 · doc4.xml · nonDerivative · entry 3

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,770

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-21-007547 · doc4.xml · nonDerivative · entry 2

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,208

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-21-007547 · doc4.xml · nonDerivative · entry 1

BENZENO SHARON · CIK 0001780854 · Chief Business Development Off

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,604

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 16, 2020.

SEC source: 0001209191-21-006578 · doc4.xml · derivative · entry 7

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,792

Underlying: Common Stock · 1,771 shares

Expires 2028-04-24

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

F6 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-006578 · doc4.xml · derivative · entry 6

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,125

Underlying: Common Stock · 1,042 shares

Expires 2029-04-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

F5 · derivative.exercise_date: The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

SEC source: 0001209191-21-006578 · doc4.xml · nonDerivative · entry 5

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,300

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.46 to 58.18, inclusive.

SEC source: 0001209191-21-006578 · doc4.xml · nonDerivative · entry 4

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,928

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.34 to 57.12, inclusive.

SEC source: 0001209191-21-006578 · doc4.xml · nonDerivative · entry 3

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,018

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.17 to 56.00, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-006578 · doc4.xml · nonDerivative · entry 2

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,113

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

SEC source: 0001209191-21-006578 · doc4.xml · nonDerivative · entry 1

Taylor Stacy L · CIK 0001799081 · SVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,342

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020.

SEC source: 0001209191-21-006577 · doc4.xml · derivative · entry 5

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 95,000

Underlying: Common Stock · 15,000 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-006577 · doc4.xml · nonDerivative · entry 4

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F4 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.27 to 58.18, inclusive.

SEC source: 0001209191-21-006577 · doc4.xml · nonDerivative · entry 3

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,796

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F3 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.26 to 57.14, inclusive.

SEC source: 0001209191-21-006577 · doc4.xml · nonDerivative · entry 2

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,706

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F2 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.20 to 56.07, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

SEC source: 0001209191-21-006577 · doc4.xml · nonDerivative · entry 1

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

SEC source: 0001209191-21-006576 · doc4.xml · derivative · entry 10

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 50,000 shares

Expires 2025-08-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 8

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.34 to 58.18, inclusive.

SEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 7

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,184

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F6 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.34 to 57.33, inclusive.

SEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 6

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,888

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

F5 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.14 to 56.12, inclusive.

SEC source: 0001209191-21-006576 · doc4.xml · nonDerivative · entry 5

Cohen Chad M · CIK 0001524314 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2020.

SEC source: 0001209191-21-005936 · doc4.xml · nonDerivative · entry 13

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,739,780

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F13 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $57.65 to 58.03, inclusive.

SEC source: 0001209191-21-005936 · doc4.xml · nonDerivative · entry 12

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,742,080

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F12 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.65 to 57.64, inclusive.

SEC source: 0001209191-21-005936 · doc4.xml · nonDerivative · entry 11

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,746,380

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F11 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $55.62 to 56.48, inclusive.

SEC source: 0001209191-21-005936 · doc4.xml · nonDerivative · entry 10

ROBINS CHAD M · CIK 0001780649 · Director · CEO and Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,749,180

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 22, 2020.

F10 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $54.50 to 55.31, inclusive.

SEC source: 0001209191-21-006312 · doc4.xml · derivative · entry 10

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 110,000

Underlying: Common Stock · 15,000 shares

Expires 2025-06-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F8 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001209191-21-006312 · doc4.xml · nonDerivative · entry 8

RUBINSTEIN JULIE · CIK 0001780664 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 20, 2020.

F7 · price: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $56.44 to 57.04, inclusive.